ICON plc Schedules First Quarter 2023 Earnings Conference Call

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 5, 2023

Founders First Capital Partners Sponsors Women in Cloud to Foster Financial Opportunities for Women Tech Founders • Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FD • Builders FirstSource Raises Over $1.2 Million at its Swing for the Cure Golf Charity Event for The Leukemia & Lymphoma Socie • New Web Addresses Pave the Way for LGBTQ+ Businesses to Thrive and Connect • Baidu's 2022 ESG Report Highlights "Safe and Controllable" as Highest Principle of AI Ethics • Bruker Launches timsTOF Ultra Mass Spectrometer with Transformative Sensitivity, 300 Hz PASEF MS/MS, and VistaScan™ for En • Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab • Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States • The Executive Leadership Council Announces the Appointment of Fabian Milburn as Chief Legal and Human Resources Officer • Hot Deal Alert: Domino's® Pizza is 50% Off This Week! • Avalon Assisted Living at Hillsborough Partners with Quake Global to Improve Quality of Care. • Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany • U.S. Institute of Peace Opens Nominations for 2023 Women Building Peace Award • AlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of B • Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on) • ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care • AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity • PreOmics Introduces New ENRICH-iST Kits and Novel Workflow for Unbiased, Affordable Plasma and Serum Proteomics by LC-MS • Dr. Jen Ashton's "BETTER" Hits Newsstands Nationwide Today • Operation Homefront presents Cornerstone Award to Bob Deforge of Pratt & Whitney

ICON plc Schedules First Quarter 2023 Earnings Conference Call

DUBLIN , March 29 /Businesswire/ - ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 27, 2023 at 8:00am ET.

Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “Events”. A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,100 employees in 111 locations in 53 countries as at December 31, 2022. For further information about ICON, visit: www.iconplc.com.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

Source: ICON plc

ICON/ICLR-G